Endocrine Month in Review: July 2021

July's month in review features stories related to new diabetes medications, National Kidney Foundation guidance, and FDA news. Check back in during the last weekend of each month for the next Endocrine Month in Review.

Editor's note: Clicking on the center of a slide will redirect users to the content associated with that slide.

Top Stories of July 2021:

  1. FDA Approves Semglee, Its First Interchangeable Biosimilar Insulin Product
    Announced on July 28, insulin glargine-yfgn (Semglee) becomes the first interchange biosimilar insulin product to receive approval in the FDA's history and is expected to be available by the end of the year.
  2. Finerenone (KERENDIA) Approved for Chronic Kidney Disease Associated with Type 2 Diabetes
    With approval on July 9, finerenone (Kerendia) becomes the first nonsteroidal mineralocorticoid receptor antagonist to receive approval for use in adults with chronic kidney disease associated with type 2 diabetes.
  3. Exenatide Extended-Release Receives Historic FDA Approval for Use in Pediatric Type 2 Diabetes
    With approval, exenatide extended-release (BYDUREON BCise) becomes the first weekly GLP-1 RA therapy to receive approval for improving glycemic control in pediatric patients aged 10-17 years with type 2 diabetes.
  4. FDA Approves Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy
    With approval announced on July 19, HFX becomes the only spinal cord stimulation therapy approved by the FDA with a specific indication for painful diabetic neuropathy.
  5. National Kidney Foundation Provides Updated Guidelines for Kidney Transplants
    The National Kidney Foundation released a position statement on July 27 providing new guidance related to kidney transplants in the US.